Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Status: | Recruiting |
---|---|
Conditions: | Lung Cancer, Lung Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | February 28, 2019 |
End Date: | September 30, 2021 |
INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous
non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or
without pembrolizumab works better in treating patients with non-squamous non-small cell
cancer.
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous
non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or
without pembrolizumab works better in treating patients with non-squamous non-small cell
cancer.
PRIMARY OBJECTIVES:
I. To evaluate overall survival (OS) in each of the 2 experimental arms (Arms A and B) to
control (Arm C).
SECONDARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) per Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 for Arm C versus each of Arms A and B.
II. To evaluate best objective response rates per RECIST 1.1 for Arm C versus each of Arms A
and B.
III. To estimate toxicity within each of the treatment arms via the Common Terminology
Criteria for Adverse Events (CTCAE) criteria.
IV. To compare outcomes between Arms A and B. V. To compare outcomes by treatment arm within
subgroups defined by a cutpoint of PD-L1 expression at >= 50%.
BIOMARKER OBJECTIVES:
I. To collect and bank tissue and blood for future research studies, including potential
development of a prognostic and predictive signature for MK-3475 (pembrolizumab) in
combination with chemotherapy versus MK-3475 (pembrolizumab) alone.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles
repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable
toxicity. At time of disease progression, patients receive pemetrexed IV over 10 minutes and
carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles
in the absence of disease progression or unacceptable toxicity. Patients then may receive
pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM B: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21
days for up to 2 years in the absence of disease progression or unacceptable toxicity. At
time of disease progression, patients receive pembrolizumab IV over 30 minutes, pemetrexed IV
over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days
for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients
then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1.
Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease
progression or unacceptable toxicity and until to disease progression for pemetrexed.
ARM C: Patients receive patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over
10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for
up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then
receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles
repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease
progression or unacceptable toxicity and until to disease progression for pemetrexed.
After completion of study treatment, patients are followed up for 5 years.
I. To evaluate overall survival (OS) in each of the 2 experimental arms (Arms A and B) to
control (Arm C).
SECONDARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) per Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 for Arm C versus each of Arms A and B.
II. To evaluate best objective response rates per RECIST 1.1 for Arm C versus each of Arms A
and B.
III. To estimate toxicity within each of the treatment arms via the Common Terminology
Criteria for Adverse Events (CTCAE) criteria.
IV. To compare outcomes between Arms A and B. V. To compare outcomes by treatment arm within
subgroups defined by a cutpoint of PD-L1 expression at >= 50%.
BIOMARKER OBJECTIVES:
I. To collect and bank tissue and blood for future research studies, including potential
development of a prognostic and predictive signature for MK-3475 (pembrolizumab) in
combination with chemotherapy versus MK-3475 (pembrolizumab) alone.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles
repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable
toxicity. At time of disease progression, patients receive pemetrexed IV over 10 minutes and
carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles
in the absence of disease progression or unacceptable toxicity. Patients then may receive
pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM B: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21
days for up to 2 years in the absence of disease progression or unacceptable toxicity. At
time of disease progression, patients receive pembrolizumab IV over 30 minutes, pemetrexed IV
over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days
for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients
then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1.
Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease
progression or unacceptable toxicity and until to disease progression for pemetrexed.
ARM C: Patients receive patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over
10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for
up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then
receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles
repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease
progression or unacceptable toxicity and until to disease progression for pemetrexed.
After completion of study treatment, patients are followed up for 5 years.
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed stage IV non-squamous
non‐small cell lung cancer (NSCLC) (includes M1a, M1b stage disease, American Joint
Committee on Cancer [AJCC] 8th edition). Patients with T4NX disease (stage IIIB) with
nodule in ipsilateral lung lobe are eligible if they are not candidates for combined
chemotherapy and radiation
- Patients must have PD-L1 expression Tumor Proportion Score (TPS) >= 1% in tumor cells.
The assay must have been performed by a Clinical Laboratory Improvement Act (CLIA) (or
equivalent) certified laboratory
- Patients must have measurable or non-measurable disease. Presence of malignant pleural
fluid alone is allowed as study eligibility.
- NOTE: If patient receives pemetrexed, follow institutional guidelines to drain
fluids
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 to 1
- Patients must NOT have received the following:
- Prior systemic chemotherapy or immunotherapy for advanced metastatic NSCLC.
Patients treated with any prior checkpoint inhibitors for lung cancer are
ineligible. Chemotherapy for non-metastatic disease (e.g. adjuvant therapy) or
immunotherapy for locally advanced stage III disease is allowed if at least 6
months have elapsed since the prior therapy and registration. Local therapy, e.g.
palliative radiation, is allowed as long as a period of 14 days has passed since
completion
- Methotrexate (MTX) given in low doses for non-malignant conditions with last dose
at least 14 days prior to date of registration will be allowed. Other low dose
chemotherapeutics for non-malignant conditions will be considered, but review by
the study chair is required
- Patients with known EGFR mutations (except exon 20 insertion), BRAF mutations (V600)
or ALK or ROS1 translocations that can be treated with oral tyrosine kinase inhibitors
are excluded
- Patients with symptomatic brain metastases are excluded. Patients with treated or
asymptomatic brain metastases are eligible if off steroids for at least 14 days prior
to protocol treatment. Anticonvulsants are allowed
- Patients with another active malignancy within the last 2 years are excluded.
Adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
adequately treated stage I or II cancer from which the patient is currently in
complete remission, or any other cancer from which the patient has been disease free
for five years are permitted
- Patients must not have known pre-existing and clinically active interstitial lung
disease, or a known history of (non infectious) pneumonitis that required steroids, or
current pneumonitis
- Patients must not have significant gastrointestinal disorders with diarrhea as a major
symptom (e.g. Crohn's disease, malabsorption, etc.)
- Patients must not have history of auto-immune condition requiring ongoing or
intermittent systemic treatment in the past 2 years (i.e. with use of disease
modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy
(e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for
adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
treatment
- Patients must not have history of clinically relevant cardiovascular abnormalities
such as uncontrolled hypertension, congestive heart failure, New York Heart
Association (NYHA) classification of 3, unstable angina or poorly controlled
arrhythmia, or myocardial infarction within 6 months prior to registration
- Patients must not have any other concomitant serious illness or organ system
dysfunction that in the opinion of the investigator would either compromise patient
safety or interfere with the evaluation of the safety of the study drug
- Patients must not receive any other investigational agents during the course of
therapy
- Women must not be pregnant or breast-feeding due to potential harm to the fetus or
infant from cytotoxic chemotherapy and the unknown risk of MK-3475 (pembrolizumab).
Patients must also not expect to conceive or father children from the time of
registration, while on study treatment, and continue for 120 days after the last dose
of study treatment
- All females of childbearing potential must have a blood test or urine study
within 72 hours prior to registration to rule out pregnancy
- A female of childbearing potential is any woman, regardless of sexual orientation
or whether they have undergone tubal ligation, who meets the following criteria:
has achieved menarche at some point; has not undergone a hysterectomy or
bilateral oophorectomy; or has not been naturally postmenopausal (amenorrhea
following cancer therapy does not rule out childbearing potential) for at least
24 consecutive months (i.e., has had menses at any time in the preceding 24
consecutive months)
- Women of childbearing potential and sexually active males must use an accepted and
effective method of contraception or abstain from sexual intercourse from time of
registration, while on study treatment, and continue for 120 days after the last dose
of study treatment
- Absolute neutrophil count (ANC) >= 1500/mm^3 (within 14 days of randomization)
- Platelets >= 100,000/mm^3 (within 14 days of randomization)
- Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 Or if patient on
therapeutic anticoagulation, PT/INR =< 3.0 (within 14 days of randomization)
- Partial thromboplastin time (PTT) =< institutional upper limit of normal (ULN) OR, if
patient is on therapeutic anticoagulation, PTT must be =< 1.5 x ULN (within 14 days of
randomization)
- Total bilirubin =< 1.5 mg/dL (obtained within 14 days of randomization)
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 5
x upper limit of normal (ULN) (obtained within 14 days of randomization)
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 5 x
upper limit of normal (ULN) (obtained within 14 days of randomization)
- Calculated creatinine clearance >= 45ml/min to be eligible to receive pemetrexed
(obtained within 14 days prior to randomization)
- Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) (obtained within
14 days prior to randomization)
- Patients must not have a known history of active tuberculosis (TB)
- Patients must not have a diagnosis of immunodeficiency or receive systemic steroid
therapy or any other form of immunosuppressive therapy within 7 days prior to the
first dose of protocol treatment
- Patients must not have received a live vaccine within 30 days prior to randomization.
Seasonal flu vaccines that do not contain live virus are permitted
- Patients who are known to be human immunodeficiency virus (HIV) positive are eligible
if they meet the following eligibility requirements:
- They must be stable on their anti-retroviral regimen, and they must be healthy
from an HIV perspective
- They must have a CD4+ T-cell count 250 cells/mcL
- They must not be receiving prophylactic therapy for an opportunistic infection
- Patients must not have known active hepatitis B (e.g., hepatitis B virus surface
antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C Virus [HCV] ribonucleic
acid [RNA] [qualitative] is detected)
We found this trial at
189
sites
2460 West Horizon Ridge Parkway
Henderson, Nevada 89052
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Richard D. Hall
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Mei Tang
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Balazs Halmos
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Balazs Halmos
Phone: 718-379-6866
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Chicago, Illinois 60625
Principal Investigator: Elyse A. Lambiase
Phone: 773-878-8200
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: David M. King
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Badi El Osta
Phone: 404-321-6111
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
Denver, Colorado 80206
Principal Investigator: Keren Sturtz
Phone: 877-225-5654
Click here to add this to my saved trials
3773 Chry Crk North Dr # 101
Denver, Colorado 80209
Denver, Colorado 80209
Principal Investigator: Keren Sturtz
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
4567 E 9th Ave
Denver, Colorado 80220
Denver, Colorado 80220
(303) 320-2121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Robert J. Behrens
Phone: 515-282-2200
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
Des Moines, Iowa 50316
(515) 263-5612
Principal Investigator: Robert J. Behrens
Phone: 515-241-8704
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
1202 East Locust Street
Emmett, Idaho 83617
Emmett, Idaho 83617
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Englewood, Colorado 80113
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
501 E. Hampden Ave.
Englewood, Colorado 80113
Englewood, Colorado 80113
303-788-5000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Ephrata, Pennsylvania 17522
Principal Investigator: Dan Sotirescu
Phone: 717-721-4840
Click here to add this to my saved trials
Ephrata, Pennsylvania 17522
Principal Investigator: Dan Sotirescu
Phone: 888-823-5923
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
Eureka, Illinois 61530
309-467-2371
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
Fort Dodge, Iowa 50501
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
802 Kenyon Road
Fort Dodge, Iowa 50501
Fort Dodge, Iowa 50501
Principal Investigator: Robert J. Behrens
Phone: 515-574-8302
Click here to add this to my saved trials
550 Osborne Rd NE
Fridley, Minnesota 55432
Fridley, Minnesota 55432
(763) 236-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Galesburg, Illinois 61401
Principal Investigator: Bryan A. Faller
Phone: 309-344-2831
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
40 V-Twin Drive
Gettysburg, Pennsylvania 17325
Gettysburg, Pennsylvania 17325
(717) 339-2640
Principal Investigator: Dan Sotirescu
Phone: 877-441-7957
Adams Cancer Center Every day across central Pennsylvania, the people of WellSpan Health work together...
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Grand Junction, Colorado 81502
Principal Investigator: Keren Sturtz
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
Click here to add this to my saved trials
1400 29th Street South
Great Falls, Montana 59405
Great Falls, Montana 59405
406-454-2171
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Great Falls Clinic Founded in 1917, the Great Falls Clinic is the fourth oldest medical...
Click here to add this to my saved trials
1801 16th St
Greeley, Colorado 80631
Greeley, Colorado 80631
(970) 352-4121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
North Colorado Medical Center NCMC is a fully accredited, private, non-profit facility licensed to operate...
Click here to add this to my saved trials
773 Cherry Tree Ct
Hanover, Pennsylvania 17331
Hanover, Pennsylvania 17331
(717) 633-9573
Principal Investigator: Dan Sotirescu
Phone: 877-441-7957
Click here to add this to my saved trials
Helena, Montana 59601
Principal Investigator: Benjamin T. Marchello
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Janesville, Wisconsin 53547
Principal Investigator: Emily G. Robinson
Phone: 800-928-1103
Click here to add this to my saved trials
Jefferson, Iowa 50129
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Jefferson City, Missouri 65109
Principal Investigator: Bryan A. Faller
Phone: 573-632-4814
Click here to add this to my saved trials
Joliet, Illinois 60435
Principal Investigator: Nafisa D. Burhani
Phone: 815-730-3098
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
Kalispell, Montana 59901
(406) 752-5111
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
Click here to add this to my saved trials
205 Tenney St
Kewanee, Illinois 61443
Kewanee, Illinois 61443
309-852-0596
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Kewanee Clinic Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer...
Click here to add this to my saved trials
Lafayette, Colorado 80026
Principal Investigator: Keren Sturtz
Phone: 303-673-1622
Click here to add this to my saved trials
1111 Shadow Lane
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
6827 West Tropicana Avenue
Las Vegas, Nevada 89103
Las Vegas, Nevada 89103
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89106
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89102
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89106
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89113
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89119
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89182
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials